Your browser is no longer supported. Please, upgrade your browser.
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-19.07 Insider Own20.50% Shs Outstand91.46M Perf Week2.45%
Market Cap29.08B Forward P/E- EPS next Y-13.19 Insider Trans-8.61% Shs Float63.36M Perf Month3.83%
Income-1600.70M PEG- EPS next Q-4.81 Inst Own60.90% Short Float3.88% Perf Quarter-16.06%
Sales308.90M P/S94.13 EPS this Y-13.80% Inst Trans-1.01% Short Ratio9.45 Perf Half Y12.14%
Book/sh43.78 P/B7.30 EPS next Y20.70% ROA-22.30% Target Price358.95 Perf Year95.79%
Cash/sh52.89 P/C6.04 EPS next 5Y37.00% ROE-31.80% 52W Range155.16 - 388.97 Perf YTD23.69%
Dividend- P/FCF- EPS past 5Y-60.30% ROI-37.50% 52W High-17.83% Beta0.88
Dividend %- Quick Ratio4.60 Sales past 5Y103.70% Gross Margin77.10% 52W Low105.99% ATR14.66
Employees5400 Current Ratio4.60 Sales Q/Q75.90% Oper. Margin- RSI (14)50.45 Volatility5.10% 4.79%
OptionableYes Debt/Eq0.15 EPS Q/Q114.60% Profit Margin- Rel Volume0.37 Prev Close308.78
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume260.20K Price319.61
Recom2.20 SMA200.54% SMA50-0.01% SMA2009.85% Volume97,156 Change3.51%
Mar-08-21Initiated China Renaissance Buy
Mar-01-21Downgrade CLSA Outperform → Underperform $330 → $321
Nov-09-20Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20Downgrade Piper Sandler Neutral → Underweight $175 → $185
Nov-06-20Downgrade Maxim Group Buy → Hold
Jul-10-20Downgrade CLSA Buy → Outperform
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
May-12-21 10:00AM  
May-07-21 12:00AM  
May-06-21 04:05PM  
Apr-28-21 01:19PM  
07:00AM  
Apr-12-21 01:30PM  
08:40AM  
Apr-11-21 04:00PM  
Apr-08-21 07:00AM  
07:00AM  
Apr-07-21 07:00PM  
Mar-30-21 08:30AM  
Mar-16-21 01:20PM  
Mar-10-21 04:30PM  
07:00AM  
Mar-05-21 08:30AM  
Mar-02-21 07:00AM  
Feb-27-21 01:21AM  
Feb-26-21 07:00AM  
06:41AM  
Feb-25-21 04:05PM  
Feb-17-21 05:00PM  
09:33AM  
07:00AM  
Jan-27-21 05:45PM  
Jan-26-21 10:01PM  
Jan-23-21 01:52AM  
Jan-15-21 09:34AM  
Jan-14-21 04:35PM  
Jan-13-21 11:00PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
07:00AM  
Jan-07-21 07:00AM  
Dec-27-20 11:00PM  
Dec-14-20 09:10PM  
Dec-11-20 06:17PM  
Dec-07-20 07:00PM  
10:00AM  
Dec-06-20 12:30PM  
Dec-01-20 11:00PM  
04:15PM  
Nov-23-20 07:00AM  
Nov-20-20 07:37AM  
Nov-19-20 08:00PM  
Nov-17-20 07:00AM  
Nov-07-20 08:04AM  
Nov-05-20 04:05PM  
09:00AM  
Oct-09-20 07:05AM  
Oct-06-20 07:00AM  
Oct-01-20 12:00PM  
08:15AM  
Sep-27-20 06:12AM  
Sep-21-20 07:00AM  
Sep-17-20 06:05PM  
Sep-10-20 09:00AM  
Sep-09-20 07:00AM  
Sep-04-20 09:15AM  
Aug-27-20 08:02AM  
07:00AM  
Aug-25-20 07:00AM  
Aug-24-20 08:08AM  
Aug-07-20 12:00PM  
Aug-06-20 04:05PM  
Aug-05-20 07:00AM  
Jul-27-20 09:15AM  
Jul-24-20 06:12PM  
Jul-20-20 07:53AM  
06:30AM  
Jul-17-20 09:00AM  
Jul-16-20 10:31AM  
Jul-15-20 05:00PM  
04:19AM  
Jul-14-20 03:43PM  
08:43AM  
Jul-13-20 10:51AM  
10:11AM  
07:53AM  
06:40AM  
02:03AM  
Jul-12-20 09:30PM  
08:00PM  
Jul-10-20 11:11AM  
Jul-05-20 04:04PM  
Jul-02-20 07:00AM  
Jul-01-20 06:00PM  
08:12AM  
07:00AM  
Jun-30-20 07:30PM  
Jun-22-20 09:00AM  
Jun-19-20 12:27AM  
Jun-18-20 07:30AM  
Jun-12-20 02:30AM  
Jun-05-20 07:30AM  
Jun-03-20 07:15AM  
May-29-20 08:00AM  
08:00AM  
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang XiaodongChair, Scientific Advisory BrdMay 10Option Exercise0.1347,5036,1755,747,271May 12 04:32 PM
Wang XiaodongChair, Scientific Advisory BrdMay 10Sale300.463,3941,019,7520May 12 04:32 PM
Wu XiaobinPresident, COO & GM ChinaMay 03Sale343.006,7152,303,2450May 05 04:46 PM
Huang JaneCMO, HematologyApr 29Option Exercise29.491,50044,2351,500May 03 04:35 PM
Huang JaneCMO, HematologyApr 29Sale354.921,500532,3870May 03 04:35 PM
Huang JaneCMO, HematologyMar 29Option Exercise29.491,50044,2351,500Mar 31 04:46 PM
Huang JaneCMO, HematologyMar 29Sale324.001,500485,9930Mar 31 04:46 PM
Huang JaneCMO, HematologyFeb 26Option Exercise29.491,50044,2351,500Mar 02 04:52 PM
Huang JaneCMO, HematologyFeb 26Sale320.731,500481,0990Mar 02 04:52 PM
Huang JaneCMO, HematologyJan 29Option Exercise29.491,50044,2351,500Feb 02 04:49 PM
Huang JaneCMO, HematologyJan 29Sale322.991,500484,4920Feb 02 04:49 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Option Exercise6.5012,60081,90012,600Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 15Sale344.9012,6004,345,6890Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Option Exercise6.501,4009,1001,400Jan 19 05:04 PM
Liang HowardCFO & Chief Strategy OfficerJan 14Sale344.471,400482,2560Jan 19 05:04 PM
BAKER BROS. ADVISORS LPDirectorJan 04Sale220.50121,15426,714,457968,943Jan 06 06:32 PM
Huang JaneCMO, HematologyDec 29Option Exercise29.491,50044,2351,500Dec 30 04:34 PM
Huang JaneCMO, HematologyDec 29Sale249.131,500373,6900Dec 30 04:34 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Option Exercise0.871,497,2001,300,0001,573,715Dec 16 04:43 PM
Liang HowardCFO & Chief Strategy OfficerDec 14Sale229.0491,90021,048,4540Dec 16 04:43 PM
BAKER BROS. ADVISORS LPDirectorDec 04Sale220.501,511,546333,295,893979,003Dec 04 05:24 PM
Huang JaneCMO, HematologyNov 30Option Exercise29.491,50044,2351,500Dec 02 05:01 PM
Huang JaneCMO, HematologyNov 30Sale267.821,500401,7230Dec 02 05:01 PM
Huang JaneCMO, HematologyOct 29Option Exercise29.491,50044,2351,500Nov 02 04:44 PM
Huang JaneCMO, HematologyOct 29Sale300.061,500450,0930Nov 02 04:44 PM
Wang XiaodongChair, Scientific Advisory BrdOct 16Sale320.005,0001,600,0000Oct 20 04:44 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Option Exercise6.5014,00091,00014,000Oct 07 04:50 PM
Wang XiaodongChair, Scientific Advisory BrdOct 05Sale300.005,0001,500,0000Oct 07 04:56 PM
Wu XiaobinPresident & GM ChinaOct 05Sale300.004,0001,200,0000Oct 07 04:52 PM
Liang HowardCFO & Chief Strategy OfficerOct 05Sale299.6014,0004,194,4130Oct 07 04:50 PM
Huang JaneCMO, HematologySep 29Option Exercise29.491,50044,2351,500Oct 01 04:52 PM
Huang JaneCMO, HematologySep 29Sale280.381,500420,5680Oct 01 04:52 PM
OYLER JOHNChief Executive OfficerSep 29Sale280.8223,3036,544,0300Sep 30 04:53 PM
OYLER JOHNChief Executive OfficerSep 28Sale280.0731,0008,682,0630Sep 30 04:53 PM
Wang XiaodongChair, Scientific Advisory BrdSep 25Sale280.425,0001,402,1160Sep 29 04:59 PM
Wu XiaobinPresident & GM ChinaSep 25Sale280.354,0001,121,4060Sep 29 04:57 PM
Wang XiaodongChair, Scientific Advisory BrdSep 17Sale260.275,0001,301,3560Sep 21 04:53 PM
Wu XiaobinPresident & GM ChinaSep 17Sale260.334,0001,041,3270Sep 21 04:50 PM
OYLER JOHNChief Executive OfficerSep 16Sale254.7727,2756,948,8070Sep 16 05:12 PM
OYLER JOHNChief Executive OfficerSep 15Sale254.2634,2148,699,3810Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Option Exercise6.5014,00091,00014,000Sep 16 05:10 PM
OYLER JOHNChief Executive OfficerSep 14Sale250.2519,7394,939,7820Sep 16 05:12 PM
Liang HowardCFO & Chief Strategy OfficerSep 14Sale250.2714,0003,503,7640Sep 16 05:10 PM
Huang JaneCMO, HematologySep 03Sale233.073,128729,0450Sep 08 04:44 PM
OYLER JOHNChief Executive OfficerSep 02Sale229.2227,8076,374,0240Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerSep 01Sale233.7920,2744,739,8090Sep 02 05:44 PM
OYLER JOHNChief Executive OfficerAug 31Sale240.8612,9613,121,7650Sep 02 05:44 PM
Huang JaneCMO, HematologyAug 28Option Exercise29.493,00088,4703,000Sep 01 04:41 PM
Huang JaneCMO, HematologyAug 28Sale242.213,000726,6260Sep 01 04:41 PM
OYLER JOHNChief Executive OfficerAug 21Sale240.1940,7889,796,7750Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 20Sale234.6221,5235,049,7490Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 19Sale234.5629,8667,005,2650Aug 21 05:21 PM
OYLER JOHNChief Executive OfficerAug 14Sale211.158,7051,838,0340Aug 14 05:30 PM
OYLER JOHNChief Executive OfficerAug 13Sale214.4814,4433,097,7620Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Option Exercise31.592,89791,5162,897Aug 12 05:02 PM
OYLER JOHNChief Executive OfficerAug 12Sale212.1019,8204,203,7660Aug 14 05:30 PM
Chen Timothy Yung-ChengDirectorAug 12Sale212.002,897614,1650Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Option Exercise31.591,90360,1161,903Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 11Sale213.041,903405,4090Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Option Exercise31.592,20069,4982,200Aug 12 05:02 PM
Chen Timothy Yung-ChengDirectorAug 10Sale214.042,200470,8860Aug 12 05:02 PM
Wang XiaodongChair, Scientific Advisory BrdAug 10Sale211.064,000844,2290Aug 12 04:38 PM
OYLER JOHNChief Executive OfficerAug 05Sale223.2717,2543,852,2730Aug 05 05:43 PM
OYLER JOHNChief Executive OfficerAug 04Sale220.4315,3833,390,9510Aug 05 05:30 PM
OYLER JOHNChief Executive OfficerAug 03Sale221.7825,1765,583,5750Aug 05 05:30 PM
Huang JaneCMO, HematologyJul 29Option Exercise94.943,000284,8353,000Jul 31 04:24 PM
Huang JaneCMO, HematologyJul 29Sale209.933,000629,7870Jul 31 04:24 PM
OYLER JOHNChief Executive OfficerJul 22Sale238.3427,7486,613,5030Jul 22 06:22 PM
OYLER JOHNChief Executive OfficerJul 21Sale251.8326,4136,651,6950Jul 22 06:14 PM
OYLER JOHNChief Executive OfficerJul 20Sale251.8528,7627,243,7840Jul 22 06:14 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.3112,0003,015,7400Jul 22 04:47 PM
Wang XiaodongChair, Scientific Advisory BrdJul 20Sale251.985,0001,259,8960Jul 22 04:47 PM
Wu XiaobinPresident & GM ChinaJul 20Sale250.162,600650,4070Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 17Sale245.74700172,0150Jul 21 04:50 PM
Wu XiaobinPresident & GM ChinaJul 15Sale241.112,700650,9980Jul 15 05:14 PM
Wu XiaobinPresident & GM ChinaJul 13Sale220.003,000660,0000Jul 15 05:14 PM
OYLER JOHNChief Executive OfficerJul 08Sale201.3917,5293,530,2060Jul 08 05:20 PM
Huang JaneCMO, HematologyJul 07Option Exercise160.403,921628,9283,921Jul 09 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 07Sale200.006,0001,200,0000Jul 09 04:45 PM
Huang JaneCMO, HematologyJul 07Sale200.003,921784,2000Jul 09 04:43 PM
OYLER JOHNChief Executive OfficerJul 07Sale198.8619,0233,782,9870Jul 08 05:20 PM
OYLER JOHNChief Executive OfficerJul 06Sale197.1117,3623,422,2620Jul 08 05:20 PM
OYLER JOHNChief Executive OfficerJul 01Sale191.573,816731,0160Jul 01 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale190.754,847924,5720Jul 06 04:52 PM
Huang JaneCMO, HematologyJun 29Option Exercise29.491,50044,2351,500Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 29Sale192.601,435276,3740Jul 01 04:43 PM
Liang HowardCFO & Chief Strategy OfficerJun 29Sale191.2330057,3680Jul 01 04:38 PM
Huang JaneCMO, HematologyJun 29Sale190.831,935369,2500Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Option Exercise160.402,079333,4722,079Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Sale200.292,079416,3970Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 24Sale187.3414,3812,694,1560Jun 24 08:23 PM
OYLER JOHNChief Executive OfficerJun 23Sale186.8815,0702,816,22214,381Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 23Sale186.386,0001,118,2980Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 22Sale182.4310,2811,875,60529,451Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 22Sale181.335,000906,6730Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 10Sale175.07900157,5630Jun 12 04:14 PM
Liang HowardCFO & Chief Strategy OfficerJun 08Sale170.8445377,3910Jun 10 05:17 PM
Wu XiaobinPresident & GM ChinaJun 08Sale170.832,800478,3170Jun 10 05:15 PM
Huang JaneCMO, HematologyJun 08Sale170.84631107,8000Jun 10 05:13 PM
Wang XiaodongChair, Scientific Advisory BrdJun 08Sale170.916,0001,025,4550Jun 10 05:12 PM